Present status and upcoming prospects of hedgehog pathway inhibitors in small cell lung cancer therapy

Infectious Agents and Cancer

Volumn 8, Issue 1, 2013, Pages

  Naqvi, Syed Hassan Abbas ^a   Naqvi, Syed Hassan Shiraz ^a   Bandukda, Muhammad Yasin ^a   Naqvi, Syed Mumtaz Ali ^a  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Cancer; Hedgehog; Inhibitors; Lung

Indexed keywords

ANTINEOPLASTIC AGENT; APROTININ; BETA CATENIN; CYCLOPAMINE; HEPATOCYTE NUCLEAR FACTOR 3BETA; ITRACONAZOLE; IWP 2; PROTEINASE INHIBITOR; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG; VISMODEGIB; WNT PROTEIN;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CONSTIPATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSGEUSIA; HELP SEEKING BEHAVIOR; HUMAN; LUNG SMALL CELL CANCER; MUSCLE SPASM; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STABILITY; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 84878008530     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-8-17     Document Type: Article

References (19)

1. Global cancer statistics, 2002. Parkin DM, Bray F, Ferlay J, Pisani P, CA Cancer J Clin 2005 55 74 108 10.3322/canjclin.55.2.74 15761078 (Pubitemid 40372904)
2. Hedgehog pathway inhibitors-current status and future prospects. Sheikh A, Alvi AA, Aslam HM, Infectious Agents and Cancer 2012 7 29 10.1186/1750-9378-7-29 23116301
3. Hedgehog: functions and mechanisms. Varjosalo M, Taipale J, Genes Dev 2008 22 18 2454 2472 10.1101/gad.1693608 18794343
4. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Thayer SP, Di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del Castillo C, Yajnik V, Nature 2003 425 6960 851 856 10.1038/nature02009 14520413 (Pubitemid 37355945)
5. Expression of hedgehog signaling molecules in lung cancer. Huang S, Yang L, An Y, Ma X, Zhang C, Xie G, Chen ZY, Xie J, Zhang H, Acta Histochem 2011 133 5 564 569
6. Activation of the hedgehog pathway in advanced prostate cancer. Sheng T, Li C, Zhang X, Chi S, Mol Cancer 2004 3 1 29 10.1186/1476-4598-3-29 15482598 (Pubitemid 40230543)
7. Hedgehog signaling: progenitor phenotype in small-cell lung cancer. Watkins DN, Berman DM, Baylin SB, Cell Cycle 2003 2 3 196 8 12734424
8. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Watkins DN, Berman DM, Burkholder SG, Wang B, Beachy PA, Baylin SB, Nature 2003 422 6929 313 7 10.1038/nature01493 12629553 (Pubitemid 36378358)
9. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Chen B, Dodge ME, Tang W, Nat Chem Biol 2009 5 2 100 107 10.1038/nchembio.137 19125156
10. Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Chen JK, Taipale J, Cooper MK, Beachy PA, Genes Dev 2002 16 21 2743 8 10.1101/gad.1025302 12414725 (Pubitemid 35253140)
11. Anti-tumour activity of aprotinin. Latner AL, Longstaff E, Turner GA, Br J Cancer 1974 30 1 60 7 10.1038/bjc.1974.113 4547138
12. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Lin TL, Matsui W, OncoTargets and Therapy 2012 5 547 558
13. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Kim J, Lee JJ, Kim J, Gardner D, Beachy PA, Proc Natl Acad Sci USA 2010 107 30 13432 7 10.1073/pnas.1006822107 20624968
14. Clinical experience with Hedgehog pathway inhibitors. Low JA, de Sauvage FJ, J Clin Oncol 2010 28 36 5321 6 10.1200/JCO.2010.27.9943 21041712
15. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. LoRusso PM, Rudin CM, Reddy JC, Clin Cancer Res 2011 17 8 2502 11 10.1158/1078-0432.CCR- 10-2745 21300762
16. Vismodegib. Dlugosz A, Agrawal S, Kirkpatrick P, Nat Rev Drug Discov 2012 11 6 437 438 10.1038/nrd3753 22653209
17. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. De Smaele E, Ferretti E, Gulino A, Curr Opin Investig Drugs 2010 11 6 707 18 20496266
18. Identification, Characterization, and Implications of Species-Dependent Plasma Protein Binding for the Oral Hedgehog Pathway Inhibitor Vismodegib (GDC-0449). Giannetti AM, Wong H, Dijkgraaf DJP, J Med Chem 2011 54 8 2592 2601 10.1021/jm1008924 21438527
19. Genentech, Erivedge [vismodegib; prescribing information] South San Francisco, CA: Genentech, Inc 2012 23675897